Company intelligence / Profile preview

Henlix Health Centre

Ownership: Private
Development stage: Commercial

Overview

Henlix Biotech Co., Ltd. develops innovative monoclonal antibodies, bispecific antibodies, and ADCs targeting solid tumors. Its most advanced program has reached Phase 1 clinical trials. The company leverages cutting-edge technologies to create novel antibody-based therapeutics as part of its mission to benefit patients worldwide.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyBispecific monoclonal antibodyAntibody-drug conjugate
Industry: Biotech

Beyond the preview

Go deeper on Henlix Health Centre.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Henlix Health Centre.

Explore the full profile